{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T05:30:43Z","timestamp":1793079043228,"version":"4.5.0"},"reference-count":172,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2023,3,29]],"date-time":"2023-03-29T00:00:00Z","timestamp":1680048000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"UK Department for Environment, Food and Rural Affairs (Defra), Scottish Government and Welsh Government","award":["SEV3500"],"award-info":[{"award-number":["SEV3500"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Rabies is a disease of antiquity and has a history spanning millennia ever since the first interactions between humans and dogs. The alarming fatalities caused by this disease have triggered rabies prevention strategies since the first century BC. There have been numerous attempts over the past 100 years to develop rabies vaccineswith the goal of preventing rabies in both humans and animals. Thepre-Pasteurian vaccinologists, paved the way for the actual history of rabies vaccines with the development of first generation vaccines. Further improvements for less reactive and more immunogenic vaccines have led to the expansion of embryo vaccines, tissue culture vaccines, cell culture vaccines, modified live vaccines, inactivated vaccines, and adjuvanted vaccines. The adventof recombinant technology and reverse genetics have given insight into the rabies viral genome and facilitated genome manipulations, which in turn led to the emergence of next-generation rabies vaccines, such as recombinant vaccines, viral vector vaccines, genetically modified vaccines, and nucleic acid vaccines. These vaccines were very helpful in overcoming the drawbacks of conventional rabies vaccines with increased immunogenicity and clinical efficacies. The path traversed in the development of rabies vaccines from Pasteur to the modern era vaccines, though, faced numerous challenges;these pioneering works have formed the cornerstone for the generation of thecurrent successful vaccines to prevent rabies. In the future, advancements in the scientific technologies and research focus will definitely lay the path for much more sophisticated vaccine candidates for rabies elimination.<\/jats:p>","DOI":"10.3390\/vaccines11040756","type":"journal-article","created":{"date-parts":[[2023,3,30]],"date-time":"2023-03-30T03:17:35Z","timestamp":1680146255000},"page":"756","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":55,"title":["Developments in Rabies Vaccines: The Path Traversed from Pasteur to the Modern Era of Immunization"],"prefix":"10.3390","volume":"11","author":[{"given":"Krithiga","family":"Natesan","sequence":"first","affiliation":[{"name":"KVAFSU-CVA Rabies Diagnostic Laboratory, WOAH Reference Laboratory for Rabies, Department of Veterinary Microbiology, Veterinary College, KVAFSU, Hebbal, Bengaluru 560024, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shrikrishna","family":"Isloor","sequence":"additional","affiliation":[{"name":"KVAFSU-CVA Rabies Diagnostic Laboratory, WOAH Reference Laboratory for Rabies, Department of Veterinary Microbiology, Veterinary College, KVAFSU, Hebbal, Bengaluru 560024, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7821-7427","authenticated-orcid":false,"given":"Balamurugan","family":"Vinayagamurthy","sequence":"additional","affiliation":[{"name":"ICAR-NIVEDI, Yelahanka, Bengaluru 560064, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharada","family":"Ramakrishnaiah","sequence":"additional","affiliation":[{"name":"KVAFSU-CVA Rabies Diagnostic Laboratory, WOAH Reference Laboratory for Rabies, Department of Veterinary Microbiology, Veterinary College, KVAFSU, Hebbal, Bengaluru 560024, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rathnamma","family":"Doddamane","sequence":"additional","affiliation":[{"name":"KVAFSU-CVA Rabies Diagnostic Laboratory, WOAH Reference Laboratory for Rabies, Department of Veterinary Microbiology, Veterinary College, KVAFSU, Hebbal, Bengaluru 560024, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3243-6154","authenticated-orcid":false,"given":"Anthony R.","family":"Fooks","sequence":"additional","affiliation":[{"name":"APHA Weybridge, Woodham Lane, New Haw, Addlestone, Surrey KT15 3NB, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,3,29]]},"reference":[{"key":"ref_1","first-page":"2","article-title":"Rabies is a Zoonotic Disease: A Literature Review","volume":"9","author":"Bilal","year":"2021","journal-title":"Occup. Med. Health Aff."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1099\/jgv.0.001689","article-title":"ICTV Virus Taxonomy Profile: Rhabdoviridae 2022","volume":"103","author":"Walker","year":"2022","journal-title":"J. Gen. Virol."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Hampson, K., Coudeville, L., Lembo, T., Sambo, M., Kieffer, A., Attlan, M., Barrat, J., Blanton, J.D., Briggs, D.J., and Cleaveland, S. (2015). Estimating the global burden of endemic canine rabies. PLoS Negl. Trop. Dis., 9.","DOI":"10.1371\/journal.pntd.0003786"},{"key":"ref_4","unstructured":"King, A.A., Fooks, A.R., Aubert, M., and Wandeler, A.I. (2004). Historical Perspective of Rabies in Europe and the Mediterranean Basin, OIE."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/B978-0-12-387040-7.00001-9","article-title":"Rabies virus transcription and replication","volume":"79","author":"Albertini","year":"2011","journal-title":"Adv. Virus Res."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"269","DOI":"10.4049\/jimmunol.110.1.269","article-title":"Antigenic properties of rabies virus components","volume":"110","author":"Wiktor","year":"1973","journal-title":"J. Immunol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"8096","DOI":"10.1128\/JVI.75.17.8096-8104.2001","article-title":"Host switching in lyssavirus history from the Chiroptera to the Carnivora orders","volume":"75","author":"Badrane","year":"2001","journal-title":"J. Virol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1586\/14787210.4.6.1021","article-title":"Current and future trends in the prevention, treatment and control of rabies","volume":"4","author":"Rupprecht","year":"2006","journal-title":"Expert Rev. Anti-Infect. Ther."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1086\/342387","article-title":"Emerging epidemiology of bat-associated cryptic cases of rabies in humans in the United States","volume":"35","author":"Messenger","year":"2002","journal-title":"Clin. Infect. Dis."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"17091","DOI":"10.1038\/nrdp.2017.91","article-title":"Rabies","volume":"3","author":"Fooks","year":"2017","journal-title":"Nat. Rev. Dis. Prim."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.ijid.2005.10.007","article-title":"Assessing the burden of human rabies in India: Results of a national multi-center epidemiological survey","volume":"11","author":"Sudarshan","year":"2007","journal-title":"Int. J. Infect. Dis."},{"key":"ref_12","first-page":"1012","article-title":"First case report of rabies in a wolf (Canis lupus pallipes) from India","volume":"1","author":"Isloor","year":"2014","journal-title":"J. Vet. Med. Res."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.vaccine.2018.10.103","article-title":"Evaluating new rabies post-exposure prophylaxis (PEP) regimens or vaccines","volume":"37","author":"Tarantola","year":"2019","journal-title":"Vaccine"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ijvsm.2018.05.001","article-title":"Advances in rabies prophylaxis and treatment with emphasis on immunoresponse mechanisms","volume":"6","year":"2018","journal-title":"Int. J. Vet. Sci. Med."},{"key":"ref_15","first-page":"3","article-title":"Development in Immunoprophylaxis against Rabies for Animals and Humans","volume":"2","author":"Nandi","year":"2010","journal-title":"Avicenna J. Med. Biotechnol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"197638","DOI":"10.1016\/j.virusres.2019.06.001","article-title":"Adjuvant activity of PCP-II, a polysaccharide from Poria cocos, on a whole killed rabies vaccine","volume":"270","author":"Zhang","year":"2019","journal-title":"Virus Res."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Zhu, S., and Guo, C. (2016). Rabies Control and Treatment: From Prophylaxis to Strategies with Curative Potential. Viruses, 8.","DOI":"10.3390\/v8110279"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.antiviral.2015.06.011","article-title":"Genetically modified rabies virus ERA strain is safe and induces long-lasting protective immune response in dogs after oral vaccination","volume":"121","author":"Shuai","year":"2015","journal-title":"Antivir. Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"107","DOI":"10.7774\/cevr.2015.4.1.107","article-title":"Oral immunization of mice with recombinant rabies vaccine strain (ERAG3G) induces complete protection","volume":"4","author":"Yang","year":"2015","journal-title":"Clin. Exp. Vaccine Res."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Ertl, H.C.J. (2019). New Rabies Vaccines for Use in Humans. Vaccines, 7.","DOI":"10.3390\/vaccines7020054"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/S0264-410X(99)00247-9","article-title":"Immunization of dogs with a DNA vaccine induces protection against rabies virus","volume":"18","author":"Perrin","year":"1999","journal-title":"Vaccine"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.jbiotec.2008.12.009","article-title":"High-level expression of rabies virus glycoprotein with the RNA-based semliki forest virus expression vector","volume":"139","author":"Benmaamar","year":"2009","journal-title":"J. Biotechnol."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Yale, G., Lopes, M., Isloor, S., Head, J.R., Mazeri, S., Gamble, L., Dukpa, K., Gongal, G., and Gibson, A.D. (2022). Review of oral rabies vaccination of dogs and its application in India. Viruses, 14.","DOI":"10.3390\/v14010155"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s13567-017-0459-9","article-title":"Oral vaccination of wildlife using a vaccinia-rabies-glycoprotein recombinant virus vaccine (RABORAL V-RG\u00ae): A global review","volume":"48","author":"Maki","year":"2017","journal-title":"Vet. Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"3675","DOI":"10.1016\/j.vaccine.2014.04.029","article-title":"Oral vaccination and protection of striped skunks (Mephitis mephitis) against rabies using ONRAB\u00ae","volume":"32","author":"Brown","year":"2014","journal-title":"Vaccine"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"A94","DOI":"10.1016\/j.vaccine.2018.08.034","article-title":"Introduction of intradermal rabies vaccination\u2014A paradigm shift in improving post-exposure prophylaxis in Asia","volume":"37","author":"Gongal","year":"2019","journal-title":"Vaccine"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Ertl, H.C.J. (2020). Rabies and Rabies Vaccines, Springer.","DOI":"10.1007\/978-3-030-21084-7"},{"key":"ref_28","first-page":"765","article-title":"Methode pour prevenir la rage apr\u00e8s morsue (in French)","volume":"101","author":"Pasteur","year":"1885","journal-title":"C. R. Acad. Sci."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1084\/jem.17.1.29","article-title":"The negri bodies in rabies","volume":"17","author":"Watson","year":"1913","journal-title":"J. Exp. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1586\/erv.11.140","article-title":"From brain passage to cell adaptation: The road of human rabies vaccine development","volume":"10","author":"Wu","year":"2011","journal-title":"Expert Rev. Vaccines"},{"key":"ref_31","first-page":"111","article-title":"Rabies vaccine production in animal cell cultures","volume":"34","author":"Sureau","year":"1987","journal-title":"Adv.Biochem.Engin.\/Biotechnol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/BF02142869","article-title":"\u00dcber die ImmunisierunggegenWutkrankheit (in German)","volume":"58","author":"Fermi","year":"1908","journal-title":"Z. Hyg. Infectionskrankh."},{"key":"ref_33","first-page":"1","article-title":"The preparation of a safe and efficient antirabic vaccine","volume":"44","author":"Semple","year":"1911","journal-title":"Sci. Mem. Med. Sanit Dept India."},{"key":"ref_34","first-page":"47","article-title":"An allergen-free antirabies vaccine","volume":"32","author":"Andjaparidze","year":"1965","journal-title":"Bull. World Health Organ."},{"key":"ref_35","first-page":"431","article-title":"Anti-rabies antibody responses in man to vaccine made from infected sucklingmouse brains","volume":"30","author":"Fuenzalida","year":"1964","journal-title":"Bull. World Health Organ."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1590\/S0037-86822004000100002","article-title":"Adverse reactions associated with a Fuenzalida-Palacios rabies vaccine: A quasiexperimental study","volume":"37","author":"Bonito","year":"2004","journal-title":"Rev. Soc. Bras. Med. Trop."},{"key":"ref_37","first-page":"211","article-title":"History, evolution and newer perspectives of rabies vaccines","volume":"52","author":"Vijayakumar","year":"2021","journal-title":"J. Vet. Anim. Sci."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"335","DOI":"10.4269\/ajtmh.1940.s1-20.335","article-title":"Human rabies, with special reference to virus distribution and titer","volume":"20","author":"Leach","year":"1940","journal-title":"Am. J. Trop.Med. Hyg."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"533","DOI":"10.4049\/jimmunol.60.4.533","article-title":"Studies on chick embryo adapted rabies virus: I. Culture characteristics and pathogenicity","volume":"60","author":"Koprowski","year":"1948","journal-title":"J. Immunol."},{"key":"ref_40","first-page":"869","article-title":"Study of antirabies immunization of man. Observations with HEP Flury and other vaccines, with and without hyperimmune serum, in primary and recall immunizations","volume":"17","author":"Fox","year":"1957","journal-title":"Bull. Org. Mond. Sante Bull. World Health Org."},{"key":"ref_41","unstructured":"Baer, G.M. (1991). The Natural History of Rabies, CRC Press. [2nd ed.]."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"79","DOI":"10.4049\/jimmunol.72.1.79","article-title":"Studies on chick-embryo-adapted rabies virus","volume":"72","author":"Koprowski","year":"1954","journal-title":"J. Immunol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/S1473-3099(02)00287-6","article-title":"Rabies reexamined","volume":"2","author":"Rupprecht","year":"2002","journal-title":"Lancet Infect. Dis."},{"key":"ref_44","first-page":"851","article-title":"Symbiose du virus de la rage avec les cultures cellulaires","volume":"104","author":"Stoel","year":"1930","journal-title":"Comp. R. Soc. Biol. Fil."},{"key":"ref_45","unstructured":"Baer, G.M. (1975). The Natural History of Rabies, Academic Press."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1126\/science.95.2456.102","article-title":"In vitro cultivation of the street virus of rabies","volume":"23","author":"Plotz","year":"1942","journal-title":"Science"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"223","DOI":"10.3181\/00379727-98-23997","article-title":"Growth of rabies virus in non-nervous tissue culture","volume":"98","author":"Kissling","year":"1958","journal-title":"Proc. Soc. Exp. Biol. Med."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1139\/m60-055","article-title":"Propagation of rabies virus in cultures of hamster kidney cells","volume":"6","author":"Fenje","year":"1960","journal-title":"Can. J. Microbiol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"362","DOI":"10.4049\/jimmunol.91.3.362","article-title":"Anti-rabies vaccine of tissue culture origin","volume":"91","author":"Kissling","year":"1963","journal-title":"J. Immunol."},{"key":"ref_50","first-page":"84","article-title":"Propagation of Rabies Virus in Pig Kidney Cell Culture","volume":"5","author":"Abelseth","year":"1964","journal-title":"Can. Vet. J."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/0042-6822(65)90160-1","article-title":"Growth characteristics of rabies virus in primary chick embryo cells","volume":"27","author":"Kondo","year":"1965","journal-title":"Virology"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"799","DOI":"10.3181\/00379727-131-33981","article-title":"Immunogenicity of concentrated and purified rabies vaccine of tissue culture origin","volume":"131","author":"Wiktor","year":"1969","journal-title":"Proc. Soc. Exp. Biol. Med."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/0014-4827(61)90192-6","article-title":"The serial cultivation of human diploid cell strains","volume":"25","author":"Hayflick","year":"1961","journal-title":"Exp. Cell Res."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/227168a0","article-title":"Characteristics of a human diploid cell designated MRC-5","volume":"227","author":"Jacobs","year":"1970","journal-title":"Nature"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1128\/am.22.3.358-365.1971","article-title":"Zonal-centrifuged purified duck embryo cell culture rabies vaccine for human vaccination","volume":"22","author":"Lavender","year":"1971","journal-title":"Appl. Microbiol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0092-1157(84)80019-0","article-title":"A new inactivated tissue culture rabies vaccine for use in man. Evaluation of PCEC-vaccine by laboratory tests","volume":"12","author":"Barth","year":"1984","journal-title":"J. Biol. Stand."},{"key":"ref_57","unstructured":"Centers for Disease Control and Prevention (1998). Notice to readers availability of new rabies vaccine for human use. Morb. Mortal. Wkly. Rep., 47, 12\u201319."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"3136","DOI":"10.1001\/jama.1982.03330230048030","article-title":"Neuro Paralytic illness and Human Diploid Cell Rabies Vaccine","volume":"248","author":"Bernard","year":"1982","journal-title":"J. Am. Med. Assoc."},{"key":"ref_59","unstructured":"Kurstak, E. (1984). Applied Virology, Academic Press."},{"key":"ref_60","unstructured":"Vodopija, I., Nicholson, K.G., Smerdel, S., and Bijok, U. (1985). Improvements in Rabies Post-Exposure Treatment, Institute of Public Health."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"2767","DOI":"10.1016\/j.vaccine.2014.02.040","article-title":"An animal component free medium that promotes the growth of various animal cell lines for the production of viral vaccines","volume":"32","author":"Rourou","year":"2014","journal-title":"Vaccine"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"5940","DOI":"10.1016\/j.vaccine.2013.10.043","article-title":"A next-generation, serum-free, highly purified Vero cell rabies vaccine is safe and as immunogenic as the reference vaccine Verorab\u00ae when administered according to a post-exposure regimen in healthy children and adults in China","volume":"31","author":"Li","year":"2013","journal-title":"Vaccine"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.2105\/AJPH.56.12.2106","article-title":"Potentiation of tissue culture rabies vaccine by adjuvants","volume":"56","author":"Fenje","year":"1966","journal-title":"Am. J. Public Health Nations Health"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"19","DOI":"10.7774\/cevr.2013.2.1.19","article-title":"The present and future of rabies vaccine in animals","volume":"2","author":"Yang","year":"2013","journal-title":"Clin. Exp. Vaccine Res."},{"key":"ref_65","first-page":"549","article-title":"The present status of rabies vaccine development and clinical experience with rabies vaccine","volume":"19","author":"Roumiantzeff","year":"1988","journal-title":"Southeast Asian J. Trop. Med. Public Health"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s00705-016-3128-9","article-title":"Rabies vaccine development by expression of recombinant viral glycoprotein","volume":"162","author":"Astray","year":"2017","journal-title":"Arch. Virol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/0264-410X(95)00011-O","article-title":"Adjuvants for human vaccines--current status, problems and future prospects","volume":"13","author":"Gupta","year":"1995","journal-title":"Vaccine"},{"key":"ref_68","first-page":"339","article-title":"Immunopotentiation by orally-administered Quillajasaponins: Effects in mice vaccinated intraperitoneally against rabies","volume":"74","author":"Chavali","year":"1988","journal-title":"Clin. Exp. Immunol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1002\/eji.201747150","article-title":"The vaccine adjuvant alum promotes IL-10 production that suppresses Th1 responses","volume":"48","author":"Oleszycka","year":"2018","journal-title":"Eur. J. Immunol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ijbiomac.2016.02.023","article-title":"Isatisindigotica root polysaccharides as adjuvants for an inactivated rabies virus vaccine","volume":"87","author":"Zhang","year":"2016","journal-title":"Int. J. Biol. Macromol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"5020","DOI":"10.1016\/j.vaccine.2018.07.006","article-title":"Comparison of immunogenicity, efficacy and transcriptome changes of inactivated rabies virus vaccine with different adjuvants","volume":"36","author":"Shi","year":"2018","journal-title":"Vaccine"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1186\/s12985-018-1089-1","article-title":"A CpG oligo deoxynucleotide enhances the immune response to rabies vaccination in mice","volume":"15","author":"Yu","year":"2018","journal-title":"Virol. J."},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Chen, C., Zhang, C., Li, R., Wang, Z., Yuan, Y., Li, H., Fu, Z., Zhou, M., and Zhao, L. (2019). Monophosphoryl-Lipid A (MPLA) is an Efficacious Adjuvant for Inactivated Rabies Vaccines. Viruses, 11.","DOI":"10.3390\/v11121118"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"564497","DOI":"10.3389\/fimmu.2020.564497","article-title":"\u03b2-Glucan as Trained Immunity-Based Adjuvants for Rabies Vaccines in Dogs","volume":"11","author":"Paris","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"229","DOI":"10.7774\/cevr.2021.10.3.229","article-title":"Staphylococcus aureus derived hyaluronic acid and bacillus Calmette-Gu\u00e9rin purified proteins as immune enhancers to rabies vaccine and related immuno-histopathological alterations","volume":"10","author":"Shebl","year":"2021","journal-title":"Clin. Exp. Vaccine Res."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"481","DOI":"10.3389\/fmicb.2020.00481","article-title":"Amino Acid Mutation in Position 349 of Glycoprotein Affect the Pathogenicity of Rabies Virus","volume":"11","author":"Luo","year":"2020","journal-title":"Front. Microbiol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"159","DOI":"10.7774\/cevr.2016.5.2.159","article-title":"Safety and immunogenicity of recombinant rabies virus (ERAGS) in mice and raccoon dogs","volume":"5","author":"Yang","year":"2016","journal-title":"Clin. Exp. Vaccine Res."},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Liu, X., Yang, Y., Sun, Z., Chen, J., Ai, J., Dun, C., Fu, Z.F., Niu, X., and Guo, X. (2014). A Recombinant Rabies Virus Encoding Two Copies of the Glycoprotein Gene Confers Protection in Dogs against a Virulent Challenge. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0087105"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s11262-014-1049-9","article-title":"An inactivated recombinant rabies CVS-11 virus expressing two copies of the glycoprotein elicits a higher level of neutralizing antibodies and provides better protection in mice","volume":"48","author":"Xue","year":"2014","journal-title":"Virus Genes"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"11300","DOI":"10.1073\/pnas.0905640106","article-title":"Effective preexposure and postexposure prophylaxis of rabies with a highly attenuated recombinant rabies virus","volume":"106","author":"Faber","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1186\/1743-422X-8-454","article-title":"Generation of a recombinant rabies Flury LEP virus carrying an additional G gene creates an improved seed virus for inactivated vaccine production","volume":"8","author":"Tao","year":"2011","journal-title":"Virol. J."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"3374","DOI":"10.1128\/JVI.76.7.3374-3381.2002","article-title":"Overexpression of the rabies virus glycoprotein results in enhancement of apoptosis and antiviral immune response","volume":"76","author":"Faber","year":"2002","journal-title":"J. Virol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"633776","DOI":"10.3389\/fcell.2021.633776","article-title":"A Guide to Nucleic Acid Vaccines in the Prevention and Treatment of Infectious Diseases and Cancers: From Basic Principles to Current Applications","volume":"9","author":"Qin","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"36","DOI":"10.4236\/wjv.2012.21005","article-title":"Rabies DNA Vaccines: Current Status and Future","volume":"2","author":"Ullas","year":"2012","journal-title":"World J. Vaccines"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1006\/viro.1994.1105","article-title":"Vaccination with a plasmid vector carrying the rabies virus glycoprotein gene induces protective immunity against rabies virus","volume":"199","author":"Xiang","year":"1994","journal-title":"Virology"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1479-0556-4-2","article-title":"Sustained protective rabies neutralizing antibody titers after administration of cationic lipid-formulated pDNA vaccine","volume":"4","author":"Margalith","year":"2006","journal-title":"Genet. Vaccines Ther."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1016\/j.vaccine.2009.01.128","article-title":"Rabies DNA vaccine: No impact of MHC class I and class II targeting sequences on immune response and protection against lethal challenge","volume":"27","author":"Kaur","year":"2009","journal-title":"Vaccine"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.coi.2011.03.008","article-title":"Electroporation delivery of DNA vaccines: Prospects for success","volume":"23","author":"Sardesai","year":"2011","journal-title":"Curr. Opin. Immunol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.biotechadv.2009.02.003","article-title":"Plasmid DNA vaccine vector design: Impact on efficacy, safety and upstream production","volume":"27","author":"Williams","year":"2009","journal-title":"Biotechnol. Adv."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"3888","DOI":"10.1016\/j.vaccine.2010.03.040","article-title":"Biosafety of DNA vaccines: New generation of DNA vectors and current knowledge on the fate of plasmids after injection","volume":"28","author":"Faurez","year":"2010","journal-title":"Vaccine"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"4414","DOI":"10.1016\/j.vaccine.2012.04.060","article-title":"RNA-based vaccines","volume":"30","author":"Ulmer","year":"2012","journal-title":"Vaccine"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1517\/17425247.2014.901308","article-title":"Nucleic acid vaccines: Prospects for non-viral delivery of mRNA vaccines","volume":"11","author":"Deering","year":"2014","journal-title":"Expert Opin. Drug Deliv."},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"Schnee, M., Vogel, A.B., Voss, D., Petsch, B., Baumhof, P., Kramps, T., and Stitz, L. (2016). An mRNA vaccine encoding rabies virus glycoprotein induces protection against lethal infection in mice and correlates of protection in adult and newborn pigs. PLoS Negl. Trop. Dis., 10.","DOI":"10.1371\/journal.pntd.0004746"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1080\/21645515.2016.1229719","article-title":"Recent advancements in combination subunit vaccine development","volume":"13","author":"Tan","year":"2017","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/BF01309439","article-title":"Characterization of rabies glycoprotein expressed in yeast","volume":"128","author":"Klepfer","year":"1993","journal-title":"Arch. Virol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/0264-410X(93)90379-C","article-title":"Oral vaccination of racoons (Procyon lotor) with baculovirus-expressed rabies virus glycoprotein","volume":"11","author":"Fu","year":"1993","journal-title":"Vaccine"},{"key":"ref_97","first-page":"477","article-title":"Development of an edible rabies vaccine in maize using the vnukovo strain","volume":"131","author":"Rojas","year":"2008","journal-title":"Dev. Biol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"26","DOI":"10.17221\/25\/2020-CJGPB","article-title":"Rabies virus glycoprotein produced in Nicotiana benthamiana is an immunogenic antigen in mice","volume":"57","author":"Park","year":"2021","journal-title":"Czech J. Genet. Plant Breed."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"6749","DOI":"10.1016\/j.vaccine.2008.10.020","article-title":"A synthetic peptide encompassing the G5 antigenic region of the rabies virus induces high avidity but poorly neutralizing antibody in immunized animals","volume":"26","author":"Bruegger","year":"2008","journal-title":"Vaccine"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"4648","DOI":"10.1016\/j.vaccine.2009.05.055","article-title":"Peptide mimotopes of rabies virus glycoprotein with immunogenic activity","volume":"27","author":"Houimel","year":"2009","journal-title":"Vaccine"},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"Cid, R., and Bol\u00edvar, J. (2021). Platforms for Production of Protein-Based Vaccines: From Classical to Next-Generation Strategies. Biomolecules, 11.","DOI":"10.3390\/biom11081072"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"108578","DOI":"10.1016\/j.vetmic.2020.108578","article-title":"AAV-expressed G protein induces robust humoral and cellular immune response and provides durable protection from rabies virus challenges in mice","volume":"242","author":"Liu","year":"2020","journal-title":"Vet. Microbiol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1080\/21645515.2016.1165908","article-title":"Adenoviral vector-based strategies against infectious disease and cancer","volume":"12","author":"Zhang","year":"2016","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1080\/21645515.2017.1419108","article-title":"Development of novel vaccine vectors: Chimpanzee adenoviral vectors","volume":"14","author":"Guo","year":"2018","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/978-1-4939-6869-5_1","article-title":"Development of novel vaccines against infectious diseases based on Chimpanzee adenoviral vector","volume":"1581","author":"Zhang","year":"2017","journal-title":"Methods Mol. Biol. (Clifton N. J.)."},{"key":"ref_106","doi-asserted-by":"crossref","unstructured":"Napolitano, F., Merone, R., Abbate, A., Ammendola, V., Horncastle, E., Lanzaro, F., Esposito, M., Contino, A.M., Sbrocchi, R., and Sommella, A. (2020). A next generation vaccine against human rabies based on a single dose of a chimpanzee adenovirus vector serotype C. PLoS Negl. Trop. Dis., 14.","DOI":"10.1371\/journal.pntd.0008459"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.virol.2006.07.037","article-title":"A single immunization with a recombinant canine adenovirus expressing the rabies virus G protein confers protective immunity against rabies in mice","volume":"356","author":"Li","year":"2006","journal-title":"Virology"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.vaccine.2007.11.029","article-title":"Oral vaccination of dogs (Canis familiaris) with baits containing the recombinant rabies-canine adenovirus type-2 vaccine confers long-lasting immunity against rabies","volume":"26","author":"Zhang","year":"2008","journal-title":"Vaccine"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.virol.2017.08.027","article-title":"Immunogenicity of ORFV-based vectors expressing the rabies virus glycoprotein in livestock species","volume":"511","author":"Martins","year":"2017","journal-title":"Virology"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1080\/01652176.2021.1930277","article-title":"Immunogenicity of replication-deficient vesicular stomatitis virus based rabies vaccine in mice","volume":"41","author":"Park","year":"2021","journal-title":"Vet. Q."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.virs.2022.02.008","article-title":"A single dose of recombinant VSV-RABVG vaccine provides full protection against RABV challenge","volume":"37","author":"Liang","year":"2022","journal-title":"Virol. Sin."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"5352","DOI":"10.1016\/j.vaccine.2016.08.088","article-title":"Infectivity of attenuated poxvirus vaccine vectors and immunogenicity of a raccoonpox vectored rabies vaccine in the Brazilian Free-tailed bat (Tadaridabrasiliensis)","volume":"34","author":"Stading","year":"2016","journal-title":"Vaccine"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"6898","DOI":"10.1016\/j.vaccine.2017.08.055","article-title":"A novel approach to a rabies vaccine based on a recombinant single-cycle flavivirus vector","volume":"35","author":"Rumyantsev","year":"2017","journal-title":"Vaccine"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"108890","DOI":"10.1016\/j.vetmic.2020.108890","article-title":"Newcastle disease virus vectored rabies vaccine induces strong humoral and cell mediated immune responses in mice","volume":"251","author":"Debnath","year":"2020","journal-title":"Vet. Microbiol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"931043","DOI":"10.3389\/fmicb.2022.931043","article-title":"A novel rabies vaccine based on a recombinant bovine herpes virus type 1 expressing rabies virus glycoprotein","volume":"13","author":"Zhao","year":"2022","journal-title":"Front. Microbiol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"20120142","DOI":"10.1098\/rstb.2012.0142","article-title":"The elimination of fox rabies from Europe: Determinants of success and lessons for the future","volume":"368","author":"Freuling","year":"2013","journal-title":"Philos. Trans. R. Soc. B Biol. Sci."},{"key":"ref_117","first-page":"372","article-title":"Oral Immunisation of Foxes against Rabies: A Field Study","volume":"29","author":"Steck","year":"1982","journal-title":"J. Vet."},{"key":"ref_118","unstructured":"M\u00fcller, T., and Freuling, C.M. (2020). Rabies and Rabies Vaccines, Springer International Publishing."},{"key":"ref_119","doi-asserted-by":"crossref","unstructured":"M\u00fcller, T.F., Schr\u00f6der, R., Wysocki, P., Mettenleiter, T.C., and Freuling, C.M. (2015). Spatio-temporal Use of Oral Rabies Vaccines in Fox Rabies Elimination Programmes in Europe. PLoS Negl. Trop. Dis., 9.","DOI":"10.1371\/journal.pntd.0003953"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/0264-410X(94)90095-7","article-title":"Vaccination against rabies: Construction and characterization of SAG2, a double avirulent derivative of SAD Bern","volume":"12","author":"Lafay","year":"1994","journal-title":"Vaccine"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1016\/S0264-410X(96)00114-4","article-title":"Safety study of the SAG2 rabies virus mutant in several non-target species with a view to its future use for the immunization of foxes in Europe","volume":"14","author":"Masson","year":"1996","journal-title":"Vaccine"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"e201266","DOI":"10.3201\/eid2612.201266","article-title":"Role of Oral Rabies Vaccines in the Elimination of Dog-Mediated Human Rabies Deaths","volume":"26","author":"Wallace","year":"2020","journal-title":"Emerg. Infect. Dis."},{"key":"ref_123","doi-asserted-by":"crossref","unstructured":"Kamp, V.T., Friedrichs, V., Freuling, C., Vos, A., Potratz, M., Klein, A., Zaeck, L., Eggerbauer, E., Schuster, P., and Kaiser, C. (2021). Comparable long-term rabies immunity in foxes after intramuscular and oral application using a third-generation oral rabies virus vaccine. Vaccines, 9.","DOI":"10.3390\/vaccines9010049"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"4758","DOI":"10.1016\/j.vaccine.2018.01.083","article-title":"In-depth genome analyses of viruses from vaccine-derived rabies cases and corresponding live-attenuated oral rabies vaccines","volume":"37","author":"Pfaff","year":"2019","journal-title":"Vaccine"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/0264-410X(92)90351-J","article-title":"Potential pathogenicity for rodents of vaccines intended for oral vaccination against rabies: A comparison","volume":"10","author":"Artois","year":"1992","journal-title":"Vaccine"},{"key":"ref_126","doi-asserted-by":"crossref","unstructured":"Chanachai, K., Wongphruksasoong, V., Vos, A., Leelahapongsathon, K., Tangwangvivat, R., Sagarasaeranee, O., Lekcharoen, P., Trinuson, P., and Kasemsuwan, S. (2021). Feasibility and Effectiveness Studies with Oral Vaccination of Free-Roaming Dogs against Rabies in Thailand. Viruses, 13.","DOI":"10.3390\/v13040571"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"4743","DOI":"10.1016\/j.vaccine.2017.09.096","article-title":"Evaluation of immune responses in dogs to oral rabies vaccine under field conditions","volume":"37","author":"Smith","year":"2019","journal-title":"Vaccine"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.3389\/fvets.2021.737250","article-title":"Immunogenicity of the Oral Rabies Vaccine Strain SPBN GASGAS in Dogs Under Field Settings in Namibia","volume":"8","author":"Molini","year":"2021","journal-title":"Front. Vet. Sci."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"100015","DOI":"10.1016\/j.jvacx.2019.100015","article-title":"Oral bait handout as a method to access roaming dogs for rabies vaccination in Goa, India: A proof of principle study","volume":"1","author":"Gibson","year":"2019","journal-title":"Vaccine X"},{"key":"ref_130","doi-asserted-by":"crossref","unstructured":"Ertl, H.C.J. (2009). Novel vaccines to human rabies. PLoS Negl. Trop. Dis., 3.","DOI":"10.1371\/journal.pntd.0000515"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"A140","DOI":"10.1016\/j.vaccine.2018.08.039","article-title":"New human rabies vaccines in the pipeline","volume":"37","author":"Fooks","year":"2019","journal-title":"Vaccine"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"7198","DOI":"10.1016\/j.vaccine.2009.09.033","article-title":"Poxvirus-vectored vaccines for rabies\u2014A review","volume":"27","author":"Weyer","year":"2009","journal-title":"Vaccine"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"6619","DOI":"10.1016\/j.vaccine.2009.08.005","article-title":"Safety studies on an adenovirus recombinant vaccine for rabies (AdRG1.3-ONRAB) in target and non-target species","volume":"27","author":"Knowles","year":"2009","journal-title":"Vaccine"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"2804","DOI":"10.1016\/S0264-410X(00)00088-8","article-title":"Adult dogs receiving a rabies booster dose with a recombinant adenovirus expressing rabies virus glycoprotein develop high titers of neutralizing antibodies","volume":"18","author":"Tims","year":"2000","journal-title":"Vaccine"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1128\/JVI.76.6.2667-2675.2002","article-title":"Novel, chimpanzee serotype 68-based adenoviral vaccine carrier for induction of antibodies to a transgene product","volume":"76","author":"Xiang","year":"2002","journal-title":"J. Virol."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"10780","DOI":"10.1128\/JVI.77.20.10780-10789.2003","article-title":"Oral vaccination of mice with adenoviral vectors is not impaired by preexisting immunity to the vaccine carrier","volume":"77","author":"Xiang","year":"2003","journal-title":"J. Virol."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.virol.2019.07.022","article-title":"A chimpanzee adenoviral vector-based rabies vaccine protects beagle dogs from lethal rabies virus challenge","volume":"536","author":"Wang","year":"2019","journal-title":"Virology"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"163","DOI":"10.2460\/javma.240.2.163","article-title":"National surveillance for human and pet contact with oral rabies vaccine baits, 2001\u20132009","volume":"240","author":"Roess","year":"2012","journal-title":"J. Am. Vet. Med."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"624","DOI":"10.3390\/vaccines2030624","article-title":"Developments in Viral Vector-Based Vaccines","volume":"2","author":"Ura","year":"2014","journal-title":"Vaccines"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"3777","DOI":"10.1016\/j.vaccine.2021.05.002","article-title":"Safety enhancement of a genetically modified live rabies vaccine strain by introducing an attenuating Leu residue at position 333 in the glycoprotein","volume":"39","author":"Ito","year":"2021","journal-title":"Vaccine"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"632957","DOI":"10.3389\/fcell.2020.632957","article-title":"Change in the single amino acid site 83 in rabies virus glycoprotein enhances the BBB permeability and reduces viral pathogenicity","volume":"8","author":"Li","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"9650","DOI":"10.1096\/fj.201902577R","article-title":"Single amino acid change at position 255 in rabies virus glycoprotein decreases viral pathogenicity","volume":"34","author":"Luo","year":"2020","journal-title":"FASEB J."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.biologicals.2022.06.004","article-title":"Study on an attenuated rabies virus strain CTN181-3","volume":"78","author":"Shi","year":"2022","journal-title":"Biologicals"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"4518163","DOI":"10.1155\/2019\/4518163","article-title":"Evaluation of Different Stabilizers and Inactivating Compounds for the Enhancement of Vero Cell Rabies Vaccine Stability and Immunogenicity: In Vitro Study","volume":"2019","author":"Olayan","year":"2019","journal-title":"Biomed. Res. Int."},{"key":"ref_145","doi-asserted-by":"crossref","unstructured":"Byrne, J., Knobel, D., Moore, S.M., Gatrell, S., and Butaye, P. (2020). The Influence of \u03b2-1,3-1,6-Glucans on Rabies Vaccination Titers in Cats. Vet. Sci., 7.","DOI":"10.3390\/vetsci7030118"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"e0141421","DOI":"10.1128\/JVI.01414-21","article-title":"Colloidal Manganese Salt Improves the Efficacy of Rabies Vaccines in Mice, Cats, and Dogs","volume":"95","author":"Wang","year":"2021","journal-title":"J. Virol."},{"key":"ref_147","doi-asserted-by":"crossref","unstructured":"Plummer, J.R., and McGettigan, J.P. (2019). Incorporating B cell activating factor (BAFF) into the membrane of rabies virus (RABV) particles improves the speed and magnitude of vaccine-induced antibody responses. PLoS Negl. Trop. Dis., 13.","DOI":"10.1371\/journal.pntd.0007800"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1080\/22221751.2021.1923341","article-title":"A novel oral rabies vaccine enhances the immunogenicity through increasing dendritic cells activation and germinal center formation by expressing U-OMP19 in a mouse model","volume":"10","author":"Zhao","year":"2021","journal-title":"Emerg. Microbes Infect."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"104648","DOI":"10.1016\/j.yrtph.2020.104648","article-title":"Nonclinical safety assessment of repeated administration and biodistribution of a novel rabies self-amplifying mRNA vaccine in rats","volume":"113","author":"Stokes","year":"2020","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1134\/S0026893318020164","article-title":"Rabies Virus Glycoprotein with a Consensus Amino Acid Sequence and a Lysosome Targeting Signal Causes Effective Production of Antibodies in DNA-Immunized Mice","volume":"52","author":"Starodubova","year":"2018","journal-title":"Mol. Biol. (Mosk)"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.vaccine.2017.11.047","article-title":"Addition of C3d-P28 adjuvant to a rabies DNA vaccine encoding the G5 linear epitope enhances the humoral immune response and confers protection","volume":"36","year":"2018","journal-title":"Vaccine"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"108906","DOI":"10.1016\/j.vetmic.2020.108906","article-title":"Construction and evaluation of recombinant Lactobacillus plantarum NC8 delivering one single or two copies of G protein fused with a DC-targeting peptide (DCpep) as novel oral rabies vaccine","volume":"251","author":"Wang","year":"2020","journal-title":"Vet. Microbiol."},{"key":"ref_153","doi-asserted-by":"crossref","unstructured":"Shipley, R., Wright, E., Lean, F.Z.X., Selden, D., Horton, D.L., Fooks, A.R., and Banyard, A.C. (2021). Assessing Rabies Vaccine Protection against a Novel Lyssavirus, Kotalahti Bat Lyssavirus. Viruses, 13.","DOI":"10.3390\/v13050947"},{"key":"ref_154","doi-asserted-by":"crossref","unstructured":"Napolitano, F., Merone, R., Abbate, A., Ammendola, V., Horncastle, E., Lanzaro, F., Esposito, M., Contino, A.M., Sbrocchi, R., and Sommella, A. (2021). Correction: A next generation vaccine against human rabies based on a single dose of a chimpanzee adenovirus vector serotype C. PLoS Negl. Trop. Dis., 15.","DOI":"10.1371\/journal.pntd.0009348"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"12","DOI":"10.24321\/2455.7048.202215","article-title":"Survival of 21 Dogs after Post-exposure Prophylaxis using Intra-dermal Rabies Vaccine in the Pre-scapular Region and Emergency Use of Expired Equine Rabies Immunoglobulin for Local Wound Infiltration in Victims of Rabid Dog Bite using One Health Approach","volume":"7","author":"Sharma","year":"2022","journal-title":"Epidemiol. Int."},{"key":"ref_156","unstructured":"(2021). Studies on Immunogenicity and Duration of Immunity of Rabies Vaccine Administered by Different Route. [Master\u2019s Thesis, Karnataka Veterinary, Animal and Fisheries Sciences University]."},{"key":"ref_157","unstructured":"Swathi, G. (2022). Comparative Evaluation of Intradermal vis-a-vis Intramuscular Pre-Exposure Prophylactic Vaccination against Rabies in Cattle. [Master\u2019s Thesis, Karnataka Veterinary, Animal and Fisheries Sciences University]."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1016\/j.vaccine.2016.09.069","article-title":"Safety, tolerability and efficacy of intradermal rabies immunization with DebioJect\u2122","volume":"35","author":"Vescovo","year":"2017","journal-title":"Vaccine"},{"key":"ref_159","doi-asserted-by":"crossref","unstructured":"World Health Organization (2018). Rabies vaccines: WHO position paper, April 2018\u2013Recommendations. Vaccine, 36, 5500\u20135503.","DOI":"10.1016\/j.vaccine.2018.06.061"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"507","DOI":"10.3109\/13550280009091951","article-title":"Absence of the p55 Kd TNF-alpha receptor promotes survival in rabies virus acute encephalitis","volume":"6","author":"Camelo","year":"2000","journal-title":"J. Neurovirol."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1080\/13550280600848399","article-title":"Expression of Toll-like receptor 3 in the human cerebellar cortex in rabies, herpes simplex encephalitis, and other neurological diseases","volume":"12","author":"Jackson","year":"2006","journal-title":"J. Neurovirol."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"4660","DOI":"10.1016\/j.vaccine.2017.12.051","article-title":"The path towards effective antivirals against rabies","volume":"37","author":"Jochmans","year":"2019","journal-title":"Vaccine"},{"key":"ref_163","first-page":"555801","article-title":"Rabies wonderful Strategies to Escape the Immune System","volume":"11","author":"Taherizadeh","year":"2019","journal-title":"Dairy Vet. Sci. J."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"2468","DOI":"10.1016\/S0264-410X(00)00475-8","article-title":"Post-exposure DNA vaccination protects mice against rabies virus","volume":"19","author":"Lodmell","year":"2001","journal-title":"Vaccine"},{"key":"ref_165","unstructured":"Jackson, A.C., and Wunner, W.H. (2007). Rabies, Elsevier Academic Press. [2nd ed.]."},{"key":"ref_166","unstructured":"World Health Organisation (2018). Position paper on rabies vaccines. Wkly. Epidemiol. Rec., 93, 201\u2013220."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1586\/14760584.2015.973403","article-title":"Rabies vaccines: Where do we stand, where are we heading?","volume":"14","author":"Kaur","year":"2015","journal-title":"Expert Rev. Vaccines"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/B978-0-12-387040-7.00013-5","article-title":"Postexposure Prophylaxis for Rabies in Resource-Limited\/Poor Countries","volume":"79","author":"Shantavasinkul","year":"2011","journal-title":"Adv. Virus Res."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.antiviral.2014.07.013","article-title":"Enhancement of blood-brain barrier permeability is required for intravenously administered virus neutralizing antibodies to clear an established rabies virus infection from the brain and prevent the development of rabies in mice","volume":"110","author":"Huang","year":"2014","journal-title":"Antivir. Res."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1590\/S1413-86702007000200011","article-title":"Short-interfering rnas as antivirals against rabies","volume":"11","author":"Brandao","year":"2007","journal-title":"Braz. J. Infect. Dis."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1292\/jvms.13-0127","article-title":"Adeno-associated viruses serotype 2-mediated rna interference efficiently inhibits rabies virus replication in vitro and in vivo","volume":"75","author":"Wu","year":"2013","journal-title":"J. Vet. Med. Sci."},{"key":"ref_172","doi-asserted-by":"crossref","unstructured":"Scott, T.P., and Nel, L.H. (2021). Rabies Prophylactic and Treatment Options: An in vitro study of siRNA- and aptamer-based therapeutics. Viruses, 13.","DOI":"10.3390\/v13050881"}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/11\/4\/756\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:05:55Z","timestamp":1760123155000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/11\/4\/756"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,29]]},"references-count":172,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,4]]}},"alternative-id":["vaccines11040756"],"URL":"https:\/\/doi.org\/10.3390\/vaccines11040756","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,29]]}}}